Western KY Rheumatology PLLC
Welcome,         Profile    Billing    Logout  
 10 Trials 
25 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lee, Eric
RA-BRANCH, NCT04086745: A Study of Baricitinib in Participants With Rheumatoid Arthritis

Recruiting
4
1300
US
Baricitinib, LY3009104, TNF Inhibitor, Etanercept, Adalimumab
Eli Lilly and Company, Incyte Corporation
Rheumatoid Arthritis
12/24
02/26
NCT05438498: Real World Evaluation of the Effectiveness of AZD7442 for Prevention of SARS-CoV-2

Terminated
3
550
US
Evusheld (tixagevimab+cilgavimab) IM or IV, AZD7442
MediMergent, LLC
SARS-CoV-2 Infection
04/23
06/23
SELUNE, NCT04181762 / 2019-003211-57: Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis

Terminated
3
275
Europe, Canada, Japan, US, RoW
secukinumab, AIN457, Placebo
Novartis Pharmaceuticals
Lupus Nephritis
09/23
09/23
RESET-RA, NCT04539964: Vagus Nerve Stimulation for Moderate to Severe Rheumatoid Arthritis

Active, not recruiting
3
243
US
Implant Procedure, Surgical placement of vagus nerve stimulator inside the neck, Conventional Synthetic DMARD, Background therapy with conventional synthetic DMARD, Active stimulation, Non-active stimulation
SetPoint Medical Corporation
Rheumatoid Arthritis
05/24
10/27
ASTRIDE, NCT05468489: To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

Recruiting
3
200
US
Serplulimab + chemotherapy (carboplatin-etoposide), Atezolizumab + chemotherapy (carboplatin-etoposide)
Shanghai Henlius Biotech
Extensive Stage Small Cell Lung Cancer
04/25
12/25
COSTAR Lung, NCT04655976 / 2020-003433-37: Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy

Active, not recruiting
3
758
Europe, Canada, Japan, US, RoW
Cobolimab, Dostarlimab, Docetaxel
GlaxoSmithKline
Lung Cancer, Non-Small Cell
04/25
10/25
NCT05758415: Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy

Active, not recruiting
3
61
Europe, US, RoW
Secukinumab, AIN457, Placebo
Novartis Pharmaceuticals
Rotator Cuff Tendinopathy
10/24
12/24
TOPAZ-1, NCT04895241 / 2020-005775-12: A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

Checkmark Trial initiation of TOPAZ-1 trial in lupus
Jun 2021 - Jun 2021: Trial initiation of TOPAZ-1 trial in lupus
Recruiting
3
540
Europe, US, RoW
Litifilimab, BIIB059, Placebo
Biogen
Lupus Erythematosus, Systemic
09/26
03/27
VAYHIT2, NCT05653219: A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids

Recruiting
3
150
Europe, Japan, US, RoW
Ianalumab, VAY736, Eltrombopag, ETB115, Placebo
Novartis Pharmaceuticals
Primary Immune Thrombocytopenia
08/25
05/28
VAYHIT1, NCT05653349: Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)

Recruiting
3
225
Europe, Japan, US, RoW
Ianalumab, VAY736, Placebo, Corticosteroids
Novartis Pharmaceuticals
Primary Immune Thrombocytopenia (ITP)
04/26
12/28
NCT06104124: A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity

Recruiting
3
621
Europe, Canada, Japan, US, RoW
Dazodalibep, VIB 4920, MEDI 4920, Placebo
Amgen
Sjogren's Syndrome
08/26
08/26
KEYNOTE-D74, NCT05911295: Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

Recruiting
3
700
Europe, Canada, US, RoW
disitamab vedotin, RC48, RC48-ADC, pembrolizumab, KEYTRUDA®, gemcitabine, Gemzar, cisplatin, carboplatin
Seagen Inc., RemeGen Co., Ltd., Merck Sharp & Dohme LLC
Urothelial Carcinoma
06/26
04/29
AMETHYST, NCT05531565 / 2020-000727-40: A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

Recruiting
2/3
474
Europe, Canada, Japan, US, RoW
Litifilimab, BIIB059, Placebo
Biogen, Biogen Idec Research Limited
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
10/26
12/27
VITALIZE, NCT04920617 / 2021-003712-27: DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Recruiting
2b
102
Europe, Canada, US, RoW
DPX-Survivac, maveropepimut-S, Pembrolizumab, MK-3475, Keytruda, CPA, Intermittent, low-dose cyclophosphamide, Procytox, Cytoxan
ImmunoVaccine Technologies, Inc. (IMV Inc.), Merck Sharp & Dohme LLC
Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma
10/24
04/25
HARMONIC, NCT05456256: A Study of LP-300 with Carboplatin and Pemetrexed in Never Smokers with Advanced Lung Adenocarcinoma

Recruiting
2
90
Japan, US, RoW
LP-300, Tavocept, BNP7787, Dimesna, Pemetrexed, Alimta, Pemfexy, Carboplatin, Paraplatin
Lantern Pharma Inc.
Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung
12/25
06/26
NCT05996835: Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (SA-AKI)

Recruiting
2
320
Europe, Canada, Japan, US, RoW
TIN816 70 mg lyophilisate powder, Placebo
Novartis Pharmaceuticals
Acute Kidney Injury Due to Sepsis
12/25
02/26
GALACELA, NCT05856448: A Study Evaluating the Effects of GLPG3667 Administered As Oral Treatment in Adult Participants with Active Systemic Lupus Erythematosus

Recruiting
2
180
Europe, US, RoW
GLPG3667, Placebo
Galapagos NV
Systemic Lupus Erythematosus
12/25
04/26
Tamarack, NCT05551117: A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors

Hourglass Sep 2024 - Sep 2024 : Updated safety and efficacy data for mCRPC
Active, not recruiting
2
192
Europe, US, RoW
vobramitamab duocarmazine 2.0 mg (Arm A), MGC018, vobramitamab duocarmazine 2.7 mg (Arm B), vobramitamab duocarmazine, Abiraterone, Enzalutamide
MacroGenics
Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer, Androgen-Insensitive Prostatic Cancer, Androgen-Resistant Prostatic Cancer, Hormone Refractory Prostatic Cancer, Anal Cancer, Anal Neoplasm, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma, Malignant Melanoma, Melanoma, Non-small Cell Lung Cancer, Non-small Cell Carcinoma, Small-cell Lung Cancer, Small Cell Carcinoma
07/24
02/25
ACER/AMN, NCT02000141: The Australian Colonic Advanced Mucosal Neoplasia and Endoscopic Resection Study

Active, not recruiting
N/A
2000
RoW
Endoscopic Mucosal Resection
Professor Michael Bourke
Colonic Polyps
01/17
01/27
NCT02581254: Thin Wire Versus Thick Wire Snare for Cold Snare Polypectomy of Diminutive Polyps

Completed
N/A
660
RoW
Thin Wire Snare, Thick Wire Snare
Western Sydney Local Health District
Polyps
01/20
07/21
WLEvB-NBI, NCT01737567: Comparison Between White Light Endoscopy and Bright Narrow Band Imaging in Diagnosis Colonic Adenomas.

Withdrawn
N/A
600
RoW
Bright Narrow Band Imaging., White Light Endoscopy
Professor Michael Bourke
Colonic Adenomas
06/21
06/24
TEACH, NCT06524180: Can TElemedicine System Replace Doctor Consultations to Achieve Non-inferior Blood Pressure in Patients With Controlled Hypertension

Recruiting
N/A
364
RoW
Telemedicine, Usual care
Chinese University of Hong Kong
Hypertension
09/27
09/27
Desai, Kishorkumar
RA-BRANCH, NCT04086745: A Study of Baricitinib in Participants With Rheumatoid Arthritis

Recruiting
4
1300
US
Baricitinib, LY3009104, TNF Inhibitor, Etanercept, Adalimumab
Eli Lilly and Company, Incyte Corporation
Rheumatoid Arthritis
12/24
02/26
GCAptAIN, NCT04930094: Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)

Active, not recruiting
3
354
Europe, Canada, US, RoW
Secukinumab 300 mg, AIN457, Placebo, Placebo Comparator, Secukinumab 150 mg
Novartis Pharmaceuticals
Giant Cell Arteritis (GCA)
04/25
07/27
NEPTUNUS-2, NCT05349214 / 2021-005687-22: Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

Active, not recruiting
3
505
Europe, Canada, Japan, US, RoW
VAY736, Placebo
Novartis Pharmaceuticals, Novartis Pharma AG
Sjogren Syndrome
05/25
05/27

Download Options